CCS's PropheSee Boosts CGM Adherence by 46% With AI Insights
PropheSee was awarded "Best Predictive Analytics Solution" as part of the MedTech Breakthrough Awards

ST. PETERSBURG, Florida—CCS, a provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s proprietary artificial intelligence-enabled predictive analytics and intervention platform—PropheSee—effectively identified approximately 28% of 55,000 Medicare fee-for-service (FFS) patients at risk of lapsing on continuous glucose monitoring (CGM) therapy.

New Research Reveals DME Channel Provides Better Outcomes for CGM Users
Among Medicare and Medicare Advantage patients, total costs of care were 35% lower for those using a DME provider versus pharmacy

DALLAS—Patients who receive continuous glucose monitors (CGM) through durable medical equipment providers have significant advantages compared to those who receive CGM through pharmacy channels, according to newly published research. 

Study Shows CGM Devices Reduce Costs, Improve Care
CCS Medical research reveals diabetes patients receiving a CGM through a medical benefit had lower costs of care, higher device adherence & longer therapy attendance

DALLAS—CCS Medical, a clinical solutions and home-delivered medical supplies provider, announced new research results which found patients living with diabetes who use a continuous glucose monitoring (CGM) device stay on therapy longer and have a lower total cost of care when they receive their supplies through a medical benefit.